SYRE

SEC filing SYRE Expands SPY003 License Agreement with Paragon, Broadens Field to All Therapeutic Uses with Dosing Restrictions

21h ago

Insider trade Sale by Michael Thomas Henderson

24d ago

SEC filing SYRE Reports $463M Offering Proceeds, $1.2B Pro Forma Cash, SKYLINE Phase 2 Topline in Q3 2026, RA Sub-Study Accelerated

28d ago

News Organon & Co is the best performing healthcare stock in April

29d ago

Failures to deliver 30,114 shares failed to deliver

30d ago

Insider trade Sale by Scott L Burrows (Chief Financial Officer)

31d ago

Insider trade Sale by Sheldon Sloan (Chief Medical Officer)

31d ago

Insider trade Sale by Cameron Turtle (Chief Executive Officer)

31d ago

News Spyre Therapeutics prices upsized $403M stock deal; gross proceeds exceed initial $300M goal

48d ago

News Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

49d ago

SEC filing SYRE Reports $0 Revenue, $0 EPS, +9.2 Pt RHI Reduction, 40% Clinical Remission, 51% Endoscopic Improvement, Phase 2 SKYLINE Trial Success, Conference Call Today

50d ago

Insider trade Sale by Scott L Burrows (Chief Financial Officer)

90d ago

Insider trade Sale by Cameron Turtle (Chief Executive Officer)

90d ago

News Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million

99d ago

Insider trade Sale by Cameron Turtle (Chief Executive Officer)

104d ago

News Eye Care-Focused Biopharma Firm SpyGlass Files for US IPO

136d ago

News Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating

138d ago

News Spyre Therapeutics' CEO Sells 15,000 Shares

142d ago

News Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

153d ago

Scanner Unusual volume (z=9.3)

160d ago

Scanner Unusual volume (z=8.5)

161d ago

Scanner Unusual volume (z=8.5)

163d ago

Scanner Unusual volume (z=8.5)

164d ago